Divergent action of calcium channel blockers on ATP-binding cassette protein expression

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 6, 2005, Pages 787-793

  Hasegawa, Kazuhiro ^a   Wakino, Shu ^a   Kanda, Takeshi ^a   Yoshioka, Kyoko ^a   Tatematsu, Satoru ^a   Homma, Koichiro ^a   Takamatsu, Ichiro ^a   Sugano, Naoki ^a   Hayashi, Koichi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

ABCA1; Aranidipine; Calcium channel blocker; cAMP; Efonidipine; Protein kinase A

Indexed keywords

ABC TRANSPORTER A1; AMLODIPINE; ARANIDIPINE; AZELNIDIPINE; BENIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CILNIDIPINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EFONIDIPINE; GENISTEIN; JANUS KINASE 2; JANUS KINASE INHIBITOR; MESSENGER RNA; MIBEFRADIL; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICARDIPINE; NICKEL CHLORIDE; NIFEDIPINE; NILVADIPINE; VERAPAMIL; ABC TRANSPORTER; DIHYDROPYRIDINE DERIVATIVE; JAK2 PROTEIN, HUMAN; NITROPHENOL; ONCOPROTEIN; ORGANOPHOSPHORUS COMPOUND; PROTEIN TYROSINE KINASE;

ARTICLE; ATHEROSCLEROSIS; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERTENSION; INHIBITION KINETICS; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; GENETICS; PHYSIOLOGY;

ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIHYDROPYRIDINES; HUMANS; HYPERTENSION; JANUS KINASE 2; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER;

EID: 33644687864     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000187976.60262.bf     Document Type: Article

References (27)

1. Ram CV. Calcium antagonists in the treatment of hypertension. Am J Med Sci. 1985; 290:118-133.
2. Christopher P, Canzone A, Quarterly M, et al. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J Hypertens. 2000;18:1429-1436.
3. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
4. Loaldi A, Polese A, Montorsi P, et al. Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. Am J Cardiol. 1989;64:433-439.
5. Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol. 1996;16:425-430.
6. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503-1510.
7. Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949-2954.
8. Zanchetti A, Rosei EA, Dal Palu C, et al. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16:1667-1676.
9. Santamarina-Fojo S, Peterson K, Knapper C, et al. Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc Natl Acad Sci USA. 2000;97:7987-7992.
10. Suzuki S, Nishimaki-Mogami T, Tamehiro N, et al. Verapamil increases the apolipoprotein-mediated release of cellular cholesterol by induction of ABCA1 expression via Liver X receptor-independent mechanism. Arterioscler Thromb Vasc Biol. 2004;24:519-525.
11. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:1178-1184.
12. Lin G, Bornfeldt KE. Cyclic AMP-specific phosphodiesterase 4 inhibitors promote ABCA1 expression and cholesterol efflux. Biochem Biophys Res Commun. 2002;290:663-669.
13. Tang C, Vaughan AM, Oram JF. Janus kinase 2 modulates the apolipoprotein interactions with ABCA1 required for removing cellular cholesterol. J Biol Chem. 2004;279:7622-7628.
14. Masumiya H, Tanaka Y, Tanaka H, et al. Inhibition of T-type and L-type Ca2+ currents by aranidipine, a novel dihydropyridine Ca2+ antagonist. Pharmacology. 2000;61:57-61.
15. Honda M, Hayashi K, Matsuda H, et al. Divergent renal vasodilator action of L- and T-type calcium antagonists in vivo. J Hypertens. 2001;19:2031-2037.
16. See RH, Caday-Malcolm RA, Singaraja RR, et al. Protein kinase A site-specific phosphorylation regulates ATP-binding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem. 2002;277:41835-41842.
17. Santamarina-Fojo S, Remaley AT, Neufeld EB, et al. Regulation and intracellular trafficking of the ABCA1 transporter. J Lipid Res. 2001;42:1339-1345.
18. Brewer HB Jr, Remaley AT, Neufeld EB, et al. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755-1760.
19. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A. 2004;101:13032-13037.
20. Aiello RJ, Brees D, Bourassa PA, et al. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637.
21. Francone OL, Royer L, Boucher G, et al. Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages. Arterioscler Thromb Vasc Biol. 2005;25:1-8.
22. Kanda A, Haruno A, Miyoshi K, et al. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. J Cardiovasc Pharmacol 1993;22:167-175.
23. Toyoda K, Kitahara M, Yamashita T, et al. Effect of efonidipine hydrochloride (NZ-105), a new dihydropyridine calcium antagonist, on the experimental atherosclerosis in cholesterol-fed rabbits. Nippon Yakurigaku Zasshi. 1994;103:231-239.
24. Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiol. 2002;57:249-255.
25. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
26. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil upregulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292:606-609.
27. Fisslthaler B, Hinsch N, Chataigneau T, et al. Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension. 2000;36:270-275.